SCHEMBL359408

SCHEMBL359408

CCCCC(CC)CCC(C)(C)CC(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP3A4 P08684 4/20 0.41
TSHR P16473 3/20 0.41
CA2 P00918 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.35
ATM Q13315 1/20 0.33
MAPK1 P28482 1/20 0.31
OPRM1 P35372 2/20 0.31
CA1 P00915 1/20 0.31
CHRM2 P08172 1/20 0.30
HTR1A P08908 1/20 0.30
ADRA2A P08913 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
CHRM1 P11229 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
DRD3 P35462 1/20 0.30
SLC6A3 Q01959 1/20 0.30
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2098620 0.85 ALDH1A1 (0.39) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL1024159 0.84 ALDH1A1 (0.45) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL28241103 0.79 ALDH1A1 (0.48) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL28528678 0.78 ALDH1A1 (0.46) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL20609969 0.77 LMNA (0.30) TSHR
SCHEMBL6150877 0.74 OPRM1 (0.33) TSHROPRM1
SCHEMBL3884493 0.73 ALDH1A1 (0.68) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL19983267 0.73
SCHEMBL3971932 0.73 ALDH1A1 (0.42) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL20568504 0.73 ALDH1A1 (0.56) ALDH1A1TDP1CYP3A4TSHRCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2136767-B1 COSMETIC COMPOSITIONS CONTAINING ESTERS BASED ON 2-PROPYL HEPTANOL COGNIS IP MAN GMBH (DE) 2016-12-14 EP disclosed
US-8937100-B2 Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative COGNIS IP MANAGEMENT GMBH (DE) 2015-01-20 US disclosed
US-20140086863-A1 Cosmetic Composition COGNIS IP MANAGEMENT GMBH (DE) 2014-03-27 US disclosed
US-8633244-B2 Cosmetic compositions comprising esters based on 2-propylheptanol COGNIS IP MANAGEMENT GMBH (DE) 2014-01-21 US disclosed
US-8633333-B2 Cosmetic compositions comprising esters based on 2-propylheptanol COGNIS IP MANAGEMENT GMBH (DE) 2014-01-21 US disclosed
US-8592484-B2 Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing COGNIS IP MANAGEMENT GMBH (DE) 2013-11-26 US disclosed
US-8580775-B2 Use of derivatives of sinapinic acid and compositions comprising such derivatives COGNIS IP MANAGEMENT GMBH (DE) 2013-11-12 US disclosed
US-20130004555-A1 Cosmetic Compositions Comprising Esters Based on 2-Propylheptanol COGNIS IP MANAGEMENT GMBH (DE) 2013-01-03 US disclosed
US-20130006010-A1 Cosmetic Compositions Comprising Esters Based on 2-Propylheptanol COGNIS IP MANAGEMENT GMBH (DE) 2013-01-03 US disclosed
US-8288436-B2 Cosmetic compositions comprising esters based on 2-propylheptanol COGNIS IP MANAGEMENT GMBH (DE) 2012-10-16 US disclosed
EP-2233128-A1 Cosmetic composition Cognis IP Management GmbH (DE) 2010-09-29 EP disclosed
US-20100130605-A1 Use of Derivatives of Sinapinic Acid and Compositions Comprising Such Derivatives COGNIS IP MANAGEMENT GMBH (DE) 2010-05-27 US disclosed
US-20100120910-A1 Cosmetic Compositions Comprising Esters Based on 2-Propylheptanol COGNIS IP MANAGEMENT GMBH (DE) 2010-05-13 US disclosed
EP-2136767-A2 COSMETIC COMPOSITIONS COMPRISING ESTERS BASED ON 2-PROPYLHEPTANOL Cognis IP Management GmbH (DE) 2009-12-30 EP disclosed
EP-2117499-A1 USE OF DERIVATIVES OF SINAPINIC ACID AND COMPOSITIONS COMPRISING SUCH DERIVATIVES Cognis IP Management GmbH (DE) 2009-11-18 EP disclosed
WO-2008131862-A2 COSMETIC COMPOSITIONS COMPRISING ESTERS BASED ON 2-PROPYLHEPTANOL COGNIS IP MANAGEMENT GMBH (DE) 2008-11-06 WO disclosed
WO-2008107093-A1 USE OF DERIVATIVES OF SINAPINIC ACID AND COMPOSITIONS COMPRISING SUCH DERIVATIVES COGNIS IP MANAGEMENT GMBH (DE) 2008-09-12 WO disclosed
EP-1967175-A1 Use of derivatives of sinapinic acid and compositions comprising such derivatives Cognis IP Management GmbH (DE) 2008-09-10 EP disclosed
EP-1967176-A1 Use of derivatives of 4-Hydroxyphenoxy acetic acid Cognis IP Management GmbH (DE) 2008-09-10 EP disclosed
EP-0502816-A1 Coating compositions resistant to light deterioration CIBA-GEIGY AG (CH) 1992-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130605-A1 Use of Derivatives of Sinapinic Acid and Compositions Comprising Such Derivatives TYR, ASAH1, AANAT ALDH1A1 84/4885TDP1 2170/4885CYP3A4 3135/4885
US-20140086863-A1 Cosmetic Composition ASAH2, ASAH1, GLA ALDH1A1 495/4885TDP1 1574/4885CYP3A4 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.